304 related articles for article (PubMed ID: 15613472)
1. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy.
Müller P; Ceskova P; Vojtesek B
J Biol Chem; 2005 Feb; 280(8):6682-91. PubMed ID: 15613472
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization.
Peng Y; Chen L; Li C; Lu W; Chen J
J Biol Chem; 2001 Nov; 276(44):40583-90. PubMed ID: 11507088
[TBL] [Abstract][Full Text] [Related]
3. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
Li D; Marchenko ND; Schulz R; Fischer V; Velasco-Hernandez T; Talos F; Moll UM
Mol Cancer Res; 2011 May; 9(5):577-88. PubMed ID: 21478269
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 chaperones wild-type p53 tumor suppressor protein.
Walerych D; Kudla G; Gutkowska M; Wawrzynow B; Muller L; King FW; Helwak A; Boros J; Zylicz A; Zylicz M
J Biol Chem; 2004 Nov; 279(47):48836-45. PubMed ID: 15358769
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
[TBL] [Abstract][Full Text] [Related]
6. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
Blagosklonny MV; Toretsky J; Bohen S; Neckers L
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8379-83. PubMed ID: 8710879
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
8. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein.
Takimoto R; Wang W; Dicker DT; Rastinejad F; Lyssikatos J; el-Deiry WS
Cancer Biol Ther; 2002; 1(1):47-55. PubMed ID: 12174820
[TBL] [Abstract][Full Text] [Related]
9. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association.
Nagata Y; Anan T; Yoshida T; Mizukami T; Taya Y; Fujiwara T; Kato H; Saya H; Nakao M
Oncogene; 1999 Oct; 18(44):6037-49. PubMed ID: 10557093
[TBL] [Abstract][Full Text] [Related]
10. Chaperone-dependent stabilization and degradation of p53 mutants.
Muller P; Hrstka R; Coomber D; Lane DP; Vojtesek B
Oncogene; 2008 May; 27(24):3371-83. PubMed ID: 18223694
[TBL] [Abstract][Full Text] [Related]
11. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation.
Sasaki M; Nie L; Maki CG
J Biol Chem; 2007 May; 282(19):14626-34. PubMed ID: 17363365
[TBL] [Abstract][Full Text] [Related]
12. NQO1 stabilizes p53 through a distinct pathway.
Asher G; Lotem J; Kama R; Sachs L; Shaul Y
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):3099-104. PubMed ID: 11867746
[TBL] [Abstract][Full Text] [Related]
13. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
[TBL] [Abstract][Full Text] [Related]
14. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
[TBL] [Abstract][Full Text] [Related]
15. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
[TBL] [Abstract][Full Text] [Related]
16. MDM2 chaperones the p53 tumor suppressor.
Wawrzynow B; Zylicz A; Wallace M; Hupp T; Zylicz M
J Biol Chem; 2007 Nov; 282(45):32603-12. PubMed ID: 17848574
[TBL] [Abstract][Full Text] [Related]
17. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.
Bossi G; Sacchi A
Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559
[TBL] [Abstract][Full Text] [Related]
18. Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53.
King FW; Wawrzynow A; Höhfeld J; Zylicz M
EMBO J; 2001 Nov; 20(22):6297-305. PubMed ID: 11707401
[TBL] [Abstract][Full Text] [Related]
19. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
20. Novel cancer therapy by reactivation of the p53 apoptosis pathway.
Bykov VJ; Wiman KG
Ann Med; 2003; 35(7):458-65. PubMed ID: 14649328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
